Senzime AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0002478776
SEK
4.83
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Senzime AB stock-summary
stock-summary
Senzime AB
Pharmaceuticals & Biotechnology
Senzime publ AB is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Company Coordinates stock-summary
Company Details
Ulls Vag 29 , UPPSALA None : 756 51
stock-summary
Tel: 46 18 515640
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Philip Siberg
Chairman of the Board
Dr. Sorin Brull
Director
Mr. Adam Dahlberg
Director
Mr. Lennart Kalen
Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
26 Million
(Quarterly Results - Jun 2025)
Net Profit:
-34 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 836 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.30

stock-summary
Return on Equity

-34.63%

stock-summary
Price to Book

2.40